Sandoz Still Trying To Sneak Past Amgen’s Stealth Enbrel Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz appeals dismissal of suit seeking a ruling that its Enbrel biosimilar candidate does not infringe patents Amgen licensed from Roche; judge says complaint is premature until an application is filed.